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 Review Article  
An updated review on transfersomes: a novel vesicular system for transdermal drug 
delivery 
 
Abstract-  
Transdermal route is an interesting option in this respect because a transdermalroute is convenient and 
safe, avoide first pass metabolism, predictable and extended duration of activity, minimizing undesirable 
side effects, utility of short half-life drugs, improving physiological and pharmacological responses, 
avoiding the fluctuation in drug levels and inter and intra-patient variations. 
However it has got its own limitations its inability to transport large molecules, inability to overcome the 
barrier properties of stratum corneum and many more.  
Formulating the drug in a transfersome is one such approach to solve theseproblems. Transfersome, is an 
ultradeformable vesicle, elastic in nature which can squeeze itself through a pore which is many times 
smaller than its size owing to its elasticity. 
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Introduction 
Delivery via the transdermal route is an interesting option in this respect because a transdermal 
route is convenient and safe. This offers several potential advantages over conventional routes 
like the avoidance of first pass metabolism, predictable andextended duration of activity, 
minimizing undesirable side effects, utility of short half-life drugs, improving physiological and 
pharmacological responses, avoiding the fluctuation in drug levels and interand intra-patient 
variations [1]. 
The term Transfersome and the underlying concept were introduced in 1991 by Gregor Cevc. 
The name ‘Transfero’ is derived from the latin word meaning to carry across and the Greek word 
‘soma’ for a body [2].  
         In the last few years, the vesicular systems have been promoted as a mean of sustained or 
controlled release of drugs. A transfersome is a highly adaptable and stress-responsive, complex 
aggregate. Its preferred form is an ultradeformable vesiclepossessing an aqueous core surrounded 
by the complex lipid bilayer (Wikipedia). Vesicles are water-filled colloidal particles. The walls 
of these capsules consist of amphiphilic molecules (lipids and surfactants) in a bilayer 
conformation. These vesicles serve as a depot for the sustained release of active compounds in 
the case of topical formulations, as well as rate-limiting membrane barrier for the modulation of 
systemic absorption in the case of transdermal formulations [3]. 
          Transfersomal patch enhances the drug release potential of transdermal delivery systems 
and also increase the rate of skin permeation of the drug [4]. 
Advantages of transfersomes 
1. Transfersomes can deform and pass through narrowconstriction (from 5 to 10 times less 
than their own diameter) without measurable loss.  
2. They can encapsulate both hydrophilic and lipophilic moieties. They have high 
entrapment efficiency for lipophilic drug near to 90%.  
3. They can be used for both systemic as well as topical delivery of drug. 
4. They protect the encapsulated drug from metabolic degradation. 
5. Transfersomes could act as efficient carriers for low as well as high molecular weight 
drugs e.g., analgesic, corticosteroids, hormones, anticancer drugs, insulin, proteins, etc. 
6. The usage in transdermal delivery system arises due to their biocompatible and 
biodegradable nature, thus showing tremendous high entrapment efficiency. [5,6,7] 
 7. Biodegradability and lack of toxicity. [8] 
8. High deformability of this system gives better penetration of intact vesicles. 
 
Limitations of transfersomes 
1. These are chemically unstable as they are highly susceptible to oxidative degradation 
[2]. 
2. Transfersomes formulations are expensive. 
3. Purity of natural phospholipids is another criteriamilitating against adoption of 
transfersomes as drug delivery vehicles. [6,7,9] 
Transfersomes v/s other carrier systems 
Transfersomes appear to be remotely related to lipid bilayers vesicle, liposomes. Transfersomes 
differ from commonly used liposomes in that they are much more flexible and adaptable as 
shown in Table 1. High flexibility of the transfersomes membrane is result of combination of 
atleast two lipophilic/amphiphilic components (phospholipidsplus bio surfactant) with 
sufficiently different packing characteristics into a single bilayer. This aggregate deformability 
permits transfersomes to penetrate the skin. Thus, if the penetration enhancement via the 
solubilization of the skin lipids was the reason for the superior penetration capability of 
transfersomes, one would expect an even better penetration performance of the micelles. 
Transfersomes differ in at least two basic features from the mixed micelles. First a transfersomes 
is normally by one to two orders of magnitude (in size) greater than standard lipid micelles. 
Secondly each vesicular transfersomes contains a water filled core. In all these vesicles the 
highly deformable transfersomes transverse the stratum corneumand enter into the viable 
epidermis in significant quantity [5,7,9]. 
Table 1: Comparision of different vesicles 
S.N. Method Advantage Disadvantage 
 
1. 
 
Penetration 
Enhancers 
Increase penetration through 
skin and give both local and 
systemic effect 
Skin irritation Immunogenicity, 
only for low molecular weight 
drugs 
 
2. 
 
Physical methods 
e.g.iontophoresis 
Increase penetration of 
intermediate size charged 
molecule 
Only for charged drugs, transfer 
efficiency is low (less than 
10%) 
 
3. 
    
 Liposomes 
Phospholipid vesicle, 
biocompatible, biodegradable 
Less skin penetration less stable 
 
4. 
 
Proliposome 
Phospholipid vesicle, more 
stable than liposomes 
Less penetration, cause 
aggregation and fusion of 
yesicles 
 
5. 
 
Niosomes 
Proniosomes 
 
Non-ionic surfactants 
vesicles, greater stability, Will 
convert into noisome in situ, 
stable 
Less skin penetration easy 
handling But will not reach up 
to deeper skin layer 
  
6. 
 
Transfersomes 
and 
Protransfersomes 
More stable, high penetration 
due to high deformability, 
biocompatible and 
biodegradable, suitable for 
both low and high molecular 
weight and also for lipophilic 
as well as hydrophilic drugs 
and reach up to deeper skin 
layers. 
None, but for some limitations 
 
Mechanism of penetration of transfersomes 
Transfersomes are composed of phospholipids. A bilayer softening component called ‘edge 
activator’, i.e., biocompatible surfactants, are added to increase lipid flexibility and permeability 
[10]. 
The mechanism for penetration is the generation of “osmotic gradient” due to evaporation of 
water while applying the lipid suspension (Transfersomes) onthe skin surface. The transport of 
these elastic vesicles is thus independent of concentration. This osmotic gradient is 
developed due to the skin penetration barrier, prevents water loss through the skin and maintains 
a water activity difference in the viable part of the epidermis which has 75% water content and 
nearly completely dry stratum corneum, near to the skin surface having 15% water content.The 
trans-epidermal hydration provides the driving force for the transport of the vesicles [11]. 
The Transfersome thus differs from such more conventional vesicle primarily by its "softer", 
more deformable, and better adjustable artificial membrane. Another beneficial consequence of 
strong bilayer deformability is the increased Transfersome affinity to bind and retain water. 
Transfersomes when applied under suitable condition can transfer 0.1 mg of lipid per hour per 
cm2 area across the intact skin. This value is substantially higher than that which is typically 
driven by the transdermal concentration gradients [12]. 
 
 
 
Fig 1: Diagrammatic Representation of The Stratum Corneum And The Intercellular And 
Transcellular Routes of Penetration.[13] 
 
 Propensity of penetration 
The magnitude of the transport driving force, of course, also plays an important role: 
                   Flow = Area x (Barrier) Permeability x (Trans-barrier) force 
Therefore, the chemically driven lipid flow across the skin always decreases dramatically when 
lipid solution is replaced by the some amount of lipids in a suspension [14]. 
Materials and methods for preparation of transfersome 
Materials:  
The most commonly used materials in the preparation of transfersomesare phospholipids, 
surfactants, alcohol, and buffering agents. Here, each material has its own importance. 
Table 2: List of materials used in formulation of transfersomes [15-20] 
Class Example Uses 
Phospho-
lipids 
 
 
Soya phosphatidyl choline,egg, phosphatidyl 
choline,dipalmitoyl, phosphatidyl choline 
 
Vesicles forming 
Component 
Surfactan
t 
 
 
Sod. cholate, Sod. deoxycholate, Tween-80, Span-80 
 
For providing 
flexibility 
 
Alcohol 
 
Ethanol, methanol As a solvent 
 
Buffering 
agent 
 
Saline phosphate buffer (pH 6.4) 
As a hydrating 
medium 
Dye 
 
 
Rhodamine-123 Rhodamine-DHPE, Fluorescein-DHPE 
Nile-red 
 
For CSLM study 
 
All the methods of preparation of transfersomes are comprised of two steps. First, a thin film is 
prepared hydrated and then brought to the desired size by sonication; andsecondly, sonicated 
vesicles are homogenized by extrusion through a polycarbonate membrane. 
 
Preparation of lipid film                                                                                   
 
 
Hydration 
 
 
Homogenization 
 
 
Sonication 
Figure 3: Flow diagram for preparation of Transferosomes 
 
 
 
Methods: 
 Suspension homogenization process [2] 
In this process, Transfersomes are prepared by mixing an ethanolic soybean phosphatidylcholine 
solution with an appropriate amount of edge-active molecule, e.g. sodium cholate. Thisprepared 
suspension is subsequently mixed with Triethanolamine-HCl buffer to yield a total lipid 
concentration. The resulting suspension is sonicated, frozen, and thawed for 2 to 3 times. Then 
brought to the desired size and measured by using photon correlation spectroscopy. The prepared 
vesicle suspension is ultimately sterilized by filtering through a 0.2 mm micro-porous filter. The 
final vesicle size is confirmed by the dynamic light scattering technique. 
Modified handshaking process [21] 
In this process, The transfersomes are prepared by modified hand shaking, ‘lipid film hydration 
technique’. Drug, lecithin (PC) and edge activator were dissolved in ethanol: chloroform (1:1) 
mixture. Organic solvent was removed by evaporation while hand shaking abovelipid transition 
temperature (43°C). A thin lipid film was formed inside the flask wall with rotation. The thin 
film was kept overnight for complete evaporation of solvent. The film was then hydrated with 
phosphate buffer (pH 7.4) with gentle shaking for 15 minute at corresponding temperature. The 
transfersome suspension was further hydrated up to 1 hour at 2-80°C. 
Aqueous lipid suspension process [22] 
In this process, Drug-to-lipid ratio in the vehicles is fixed between 1/4 and 1/9. Depending upon 
the particular formulation type, the composition is preferred. This would ensure the high 
flexibility of the vesicle membrane in comparison to the standard phosphatidylcholine vesicles in 
the fluid phase. Specifically, vesicles with the size ranging from 100-200 nm are prepared by 
using soyphosphatidylcholine with the standard deviation of size distribution (around 30%). This 
formulation could be prepared by suspending the lipids in an aqueous phasewherein the drug is 
dissolved. Then the usage of vigorous stirring or suspension homogenization (eg. sonication) 
techniques, the average vesicle size is reduced in the original suspension. Vesicles dimension is 
finally brought to the desired value by extruding the suspension through 100-200 nm pore filters 
and finally the optimal pH value of the suspension is adjusted. 
Centrifugation process 
In this process, Phospholipids, surfactants and the drug are dissolved in alcohol. Then the solvent 
is removed by rotary evaporation under reduced pressure at 40
o
C. Final traces of solvent are 
removed under vacuum. Then the deposited lipid film is hydrated with theappropriate buffer by 
centrifuging at 60 rpm for 1 hour at room temperature. At room temperature, the resulting 
vesicles are swollen for 2 hours. The multi-lamellar lipid vesicles obtained which are further 
sonicated at room temperature. 
Optimization of formulation containing transfersomes 
There are various process variables which could affect the preparation and properties of the 
transfersomes. The preparation procedure was accordingly optimized andvalidated. The 
preparation of transfersomes involves various process variables such as: 
1. Lecithin : surfactant ratio 
2. Effect of various solvents (ethanol / isopropyl alcohol) 
3. Effect of various surfactants (Span80, Tween80)   
4. Hydration medium 
Thus the optimization procedures are conducted by selecting entrapment efficiency of the drug 
[22, 24, 27]. 
 
Characterization and evaluation of transfersomes 
Vesicle morphology 
 Vesicle Diameter 
Vesicle diameter can be determined using photon correlation spectroscopy or dynamic light 
scattering (DLS) method. Samples were prepared in distilled water, filteredthrough a 0.2 mm 
membrane filter and diluted with filtered saline and then size measurement done by using photon 
correlation spectroscopy or dynamic light scattering (DLS) measurements [23]. 
Vesicle Shape & Type 
Transfersomes vesicles can be visualized by phase contrast microscopy, TEM, with an 
accelerating voltage of 100 kv. These vesicles can be visualized without sonication by phase 
contrast microscopy by using an optical microscope etc. The stabilityof vesicle can be 
determined by assessing the size and structure of vesicles over time. Mean size ismeasured by 
Dynamic light scattering (DLS) and structural changes are observed by TEM. 
Vesicle size distribution and zeta potential 
Vesicle size, size distribution and zeta potential were determined by Dynamic Light Scattering 
Method (DLS) using a computerized inspection system by Malvern Zetasizer [5, 9]. 
Number of vesicle per cubic mm 
This is an important parameter for optimizing the composition and other processvariables. 
Non-sonicated transfersome formulations are diluted five times with 0.9% sodium chloride 
solution. Haemocytometer and optical microscope can then be used for further study. The 
Transfersomes in 80 small squares are counted and calculated using the following formula: 
 
Total number of Transfersomes per cubic mm = Total number of Transfersomes counted  
                                                                                    × dilution factor × 4000 
                                                      N = A × F × 4000 
 
Total number of transfersomes per cubic mm (N); Total number of transfersomes counted (A);  
Dilution Factor (F). 
Entrapment efficiency 
The entrapment efficiency is expressed as the percentage entrapment of the drug added. 
Entrapment efficiency was determined by first separation of the un-entrapped drugby use of 
minicolumn centrifugation method. After centrifugation, the vesicles were disrupted using 0.1% 
Triton X-100 or 50% n-propanol. The entrapment efficiency is expressed as: 
           Entrapment efficiency (EE) = (Amount entrapped / Total amount added) × 100 
Drug content 
The drug content can be determined using one of the instrumental analytical methods such as 
modified high performance liquid chromatography method (HPLC) method using a UV detector, 
column oven, auto sample, pump, and computerized analysis programdepending upon the 
analytical method of the pharmacopoeial drug [24]. 
Turbidity measurement 
Turbidity of drug in aqueous solution can be measured using nephelometer [5]. 
Surface charge and charge density 
Surface charge and Charge density of transfersomes can be determined using Zetasizer. 
Regarding the zeta potential measurements, all colloidal dispersions have a negative surface 
charge, containing Tween 80 which is a non ionic surfactant. The reason forthis result is that 
Tween 80 is a non-ionic surfactant while sodium cholate is anionic surfactant. It is speculated 
that the hydrocarbon tail of Tween 80 might be able to penetrate into the lipid bilayer. Thus, the 
incorporation of negative zeta potential increases the stability of the transfersomes. 
Occlusion effect 
 Occlusion of skin is considered to be helpful for permeation of drug in case of traditional topical 
preparations. But the same proves to be detrimental for elastic vesicles[34]. These ‘Hydrotaxis’ 
drives the vesicles from the relatively dry skin surface into water rich viable skin regions. 
However, the phenomena of occlusion prevent evaporation of water from the skin surface, thus 
affecting hydration force, eventually revealing that the occlusion imparts a disabling effect on 
vesicle permeation [25]. 
Confocal scanning laser microscopy (cslm) study 
Conventional light microscopy and electron microscopy both face problemof fixation, sectioning 
and staining of the skin samples. Often the structures to be examined are actually incompatible 
with the corresponding processing techniques; these give rise to misinterpretation, but can be 
minimized by Confocal Scanning Laser Microscopy (CSLM). In this technique lipophilic 
fluorescence markers are incorporated into the transfersomes and the light emitted by these 
markers used for following purpose: 
 For investigating the mechanism of penetration of transfersomes across the skin. 
 For determining histological organization of the skin (epidermal columns, 
interdigitation), shapes and architecture of the skin penetration pathways. 
 For comparison and differentiation of the mechanism of penetration of transfersomes 
with liposomes, niosomes and micelles. 
Different fluorescence markers used in CSLM study are as – 
1. Fluorescein- DHPE (1, 2- dihexadecanoyl- sn- glycero- 3- phosphoethanolamine- N- (5 - 
fluoresdenthiocarbamoyl), triethyl- ammonium salt) 
2. Rhodamine- DHPE (1, 2- dihexadecanoyl- sn- glycero- 3-ogisogietgabikanube- 
NLissamineTmrhodamine- B- sulfonyl), triethanol- amine salt) 
3. NBD- PE (1, 2- dihexadecanoyl- sn-glycero- 3- phosphoethanolamine- N- (7-nitro- Benz- 2- 
oxa- 1,3- diazol- 4- yl) triethanolamine salt) 
4. Nile red. 
In-vitro drug release 
In vitro drug release study is performed for determining the permeation rate. For determining in 
vitro drug release, beaker method is used in which transfersomes suspension is incubated at 32°C 
using cellophane membrane and the samples are taken at different timesand then detected by 
various analytical techniques (UV, HPLC, HPTLC) and the free drug is separated by 
minicolumn centrifugation, then the amount of drug release is calculated [26]. 
The amount of drug released is then calculated indirectly from the amount of drug entrapped at 
zero times as the initial amount (100% entrapped and 0% released) [5, 7]. 
In-vitro skin permeation studies 
Modified Franz diffusion cell with a receiver compartment volume of 50ml and effective 
diffusion area of 2.50 cm2 was used for this study. In vitro drug study was performed by using 
goat skin in phosphate buffer solution (pH 7.4). Fresh Abdominal skin of goatwere collected 
from slaughterhouse and used in the permeation experiments. Abdominal skin hairs were 
removed and the skin was hydrated in normal saline solution. The adipose tissue layer of the skin 
was removed by rubbing with a cotton swab. Skin was kept in isopropyl alcohol solution and 
stored at 0-40˚C. 
             To perform skin permeation study, treated skin was mounted horizontally on the receptor 
compartment with the stratum corneum side facing upwards towards the donor compartment of 
Franz diffusion cell. The effective permeation area of donor compartment exposed to receptor 
compartment was 2.50cm2 and capacity of receptor compartment was 50ml. The receptor 
compartment was filled with 50ml of phosphate buffer (pH 7.4) saline maintained at 37 ± 0.5˚C 
 and stirred by a magnetic bar at 100RPM. Formulation (equivalent to 10mg drug) was placed on 
the skin and the top of the diffusion cell was covered. At appropriate time intervals 1 ml aliquots 
of the receptor medium were withdrawn and immediately replaced by an equalvolume of fresh 
phosphate buffers (pH 7.4) to maintain sink conditions. Correction factors for each aliquot were 
considered in calculation of release profile. The samples were analyzed by any instrumental 
analytical technique [27, 28]. 
In vivo fate of transfersomes & kinetics of transfersomes penetration 
After having penetrated through the outermost skin layers, transfersomes reach the deeper skin 
layer. From there, they are normally washed out into the blood circulation. If it is applied under 
suitable conditions, resulting in access to all body tissues. The kinetics of this action of an 
epicutaneous application depend upon the velocity of carrier penetration as well as on the speed 
of drug distribution [29]. 
The most important single factors in this process are: 
1. Carrier in-flow 
2. Carrier accumulation at the targets site 
3. Carrier elimination 
The onset of penetration-driving force depends on the volume of thesuspension medium that 
must evaporate from the skin surface before the sufficiently strong trans-cutaneous chemical 
potential chemical potential or water activity gradient is established.  
The lag phase is duration between the time of application and the time of drug appearance in the 
body. It is always quite long, complex and strongly sensitive to the type of drug and formulation 
administration. Mostly the skin penetration lag amounts to approximately 15 min, if rapidly 
exchanging agents such as local analgesics are detected right under the skin permeability barrier. 
Less rapidly exchanging molecules or molecules measured in the blood compartment are 
typically detected with a lag time between 2 and 6 hr. Molecules that do not diffuse readily from 
the carriers or agents delivered with the suboptimal carriers normally fall in this category. The 
kinetics of vesicle penetration into and across the skin can be controlledto a large extent by 
fixing the physicochemical characteristics of the drug carrier suspension.  
Kinetics of the transfersomes penetration through the intact skin is best studied in the direct 
biological assays in which vesicle associated drugs exert their action directly under the skin 
surface. Local analgesics are useful for determining the kinetics of penetration. Various lidocaine 
loaded vesicles were left to dry out on the intact skin. Corresponding subcutaneous injection is 
used as control. The animal's sensitivity to pain at the treated site after each application was 
measured. Dermally applied standard drug carrying liposomes or simple lidocaine solution have 
never caused any analgesic effect. It was necessary to inject such agent preparations to achieve 
significant pain suppression. The lidocaine-loaded transfersomes were analgesically active even 
when applied dermally. Maximum analgesic effect with the latter type of drug application was 
typically observed 15 minutes after the drug application. The precise reach as well as kinetics of 
transfersomes penetration through the skin are affected by: drug carrier interaction, application 
condition or form, skin characteristics, applied dose [30]. 
1. Delivery of insulin: 
By transferosomes is the successful means of non invasive therapeutic use of such large 
molecular 
weight drugs on the skin. Insulin is generally administered by subcutaneous route that is 
inconvenient. Encapsulation of insulin into Transfersomes (transfersulin)overcomes the 
problems of inconvenience, larger size (making it unsuitable for transdermal delivery using 
 conventional method) along with showing 50% response as compared to subcutaneous injection 
[30,31]. 
2. Delivery of corticosteroids: 
Transferosomes have also used for the delivery of corticosteroids. Transferosomes improves the 
site specificity and overall drug safety of corticosteroid delivery into skin by optimizing the 
epicutaneously administered drug dose. Transferosomes based corticosteroids are biologically 
active at dose several times lower than the currently used formulation for thetreatment of skin 
diseases [32]. 
3. Delivery of proteins and peptides: 
Transfersomes have been widely used as a carrier for the transport of proteins and peptides. 
Proteins and peptides are large biogenic molecules which are very difficult to transport into the 
body, when given orally they are completely degraded in the GI tract and transdermal delivery 
suffers because of their large size. These are the reasons why these peptides and proteins still 
have to be introduced into the body through injections. Various approaches have been developed 
to improve these situations. The bioavaibility obtained from transferosomes is somewhatsimilar 
to that resulting from subcutaneous injection of the same protein suspension. Human serum 
albumin or gap junction protein was found to be effective in producing the immune response 
when delivered by transdermal route encapsulated in Transfersomes. Transport of certain drug 
molecules that have physicochemical which otherwise prevent them from diffusing across 
stratum corneum can be transported [33, 34]. 
.4. Delivery of Anticancer Drugs: 
Anti cancer drugs like methotrexate were tried for transdermal delivery usingtransfersome 
technology. The results were favorable. This provided a new approach for treatment especially of 
skin cancer [9, 35].  
5. Delivery of anesthetics: 
Transfersome based formulations of local anesthetics- lidocaine and tetracaine showed 
permeation equivalent to subcutaneous injections, with less than 10 min. Maximum resulting 
pain insensitivity is nearly as strong (80%) as that of a comparable subcutaneous bolus injection, 
but the effect of transferosomal anesthetics last longer [9]. 
6. Delivery of Herbal Drugs 
Transfersomes can penetrate stratum corneum and supply the nutrients locally to maintain its 
functions resulting maintenance of skin [35, 36, 37].  
Table No.3: Applications of transfersomes            
S. No Name of drug Inference 
1 
 
Curcumin 
 
Better permeation for anti inflammatory activity 
 
2 Indinavir sulfate 
 
Improved influx for activity against acquired immune 
deficiency syndrome (AIDS) 
 
3 
 
Stavudine 
 
 
Improved the in vitro skin delivery of Stavudine for 
antiretroviral activity 
 
4 
 
Norgesterol 
 
 
Improved transdermal flux 
5   
 Tetanus toxoid 
 
For transdermal immunization 
6 
Hydrocortisone 
 
 
Biologically active at dose several times lower than 
currently used formulation. 
 
7 
Interferon-α 
 
 
Efficient delivery means (because delivery other route 
is difficult). 
Controlled release. Overcome stability problem. 
 
8 
 
Ketoprofen 
 
 
Improved penetration for anti-inflammatory activity 
9 
Insulin 
 
 
Induce therapeutically significant hypoglycemia with 
good efficacy and reproducibility 
 
10 Capsaicin 
 
Increase skin penetration 
 
11 
Vincristine 
 
 
Increase entrapment efficiency 
and skin permeation 
 
12 Methotrexate 
 
Improved transdermal flux 
 
13 Oestradiol 
 
Improved transdermal flux 
 
14 Colchicine  
 
Increase skin penetration 
 
15 Tetracaine, Lignocain 
 
Suitable means for the noninvasive treatment of local 
pain on direct topical drug application. 
 
16 Corticosteroids 
 
Improved site specificity and overall drug safety. 
 
17 Human serum albumin 
 
Antibody titer is similar or even slightly higher than 
subcutaneous injection. 
 
 
Discussion and conclusion 
Transfersomes are specially optimized particles or vesicles, which can respond to an external 
stress by rapid and energetically inexpensive, shape transformations. Such highly deformable 
particles can thus be used to bring drugs across the biological permeability barriers, such as skin. 
When tested in artificial systems transfersomes can pass througheven tiny pores (100 mm) nearly 
as efficiently as water, which is 1500 times smaller.  
Ultradeformable vesicles hold great prospective in delivery of huge range of drug substances 
which includes large molecules like peptides, hormones and antibiotics, drugs with poor 
 penetration due to unfavourable physicochemical characters, drugs for quicker and targeted 
action, etc. This carrier system does not depend upon the 
concentration gradient and mainly works on the principle of hydrotaxis and elasto-mechanics. 
Transfersomes are highly deployed in the delivery of hormones, proteins, anticancer drugs, 
anesthetics and insulin transdermally. 
All above discussed properties of this technology strongly advocate its good future in 
transdermal drug delivery. Drug release can also be controlled according to therequirement. 
Thus, this approach can overcome the problems which occur in conventional techniques. 
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